Ariad Pharmaceuticals (NASDAQ:ARIA) is the biotech of the week on the Fool's weekly biotech-focused show, Biotech Banter.

Shares of the biotech have been on a bit of a roller coaster over the last year as investors went from having high hopes for Ariad Pharmaceutical's leukemia drug Iclusig to seeing the drug getting pulled from the market because the drug is linked to blood clots. After returning to the market, Ariad's shares have more than doubled off their lows, but are still well off of where they were when investors thought Iclusig could compete with Novartis' (NYSE:NVS) Gleevec and Bristol-Myers Squibb's (NYSE:BMY) Sprycel as first-line treatments.

For now Iclusig is stuck as a treatment of last resort, mostly used on patients that can't take or have failed Novartis' and Bristol-Myers Squibb's drugs, but there's potential to increase sales if Ariad Pharmaceuticals can show that the risk-benefit profile is better at lower doses. Blood thinners might also help lower the risk of blood clots.

As senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss in the video below, there's also potential for the drug to work in patients with solid tumors who might not have to take the drug for as long.

Our CIO thinks this stock will have a much better 2014
Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

David Williamson owns shares of Novartis. Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.